No Data
No Data
Jiangsu Sihuan Bioengineering Co., Ltd's (SZSE:000518) 26% Gain Last Week Benefited Both Retail Investors Who Own 56% as Well as Insiders
Jiangsu Sihuan Bioengineering: Jiangsu Sihuan Bioengineering Co., Ltd. Performance Forecast for the First Half of 2024.
Jiangsu Sihuan Bioengineering (000518.SZ): expects a loss of 10 million to 20 million yuan in the first half of the year.
On July 9th, Gelonhui reported that Jiangsu Sihuan Bioengineering (000518.SZ) released its performance forecast for the first half of 2024. According to preliminary estimates by the finance department, the net loss attributable to shareholders of the listed company is expected to be approximately RMB 20 million to RMB 10 million, an increase of approximately 47.06% to 73.53% compared to the same period last year. After deducting non-recurring gains and losses, the net loss is approximately RMB 21 million to RMB 10.5 million, an increase of approximately 44.64% to 72.32% compared to the same period last year. The basic EPS is approximately -0.0194 yuan/share to -0.0097 yuan/share. The company's business during this reporting period.
Jiangsu Sihuan Bioengineering (000518.SZ): did not provide guarantee for the loan of Sunlight Group.
Jiangsu Sihuan Bioengineering (000518.SZ) stated on the investor interaction platform on July 3 that the company did not provide guarantees for Sunlight Group's loans.
[BT Financial Report Analysis] Jiangsu Sihuan Bioengineering Q1 2024 comprehensive report: Financial data reveals the company's operational status.
As an enterprise that sells mainly pharmaceuticals, Jiangsu Sihuan Bioengineering (stock code: 000518) continues to demonstrate its stable operation in the pharmaceutical industry. The first quarter report for 2024 recently released reveals the company's latest financial status and performance to investors. Judging from the asset-liability data, the company's total assets at the end of the period reached 653 million yuan, slightly down compared to the beginning of the period, with a decrease of 1.13%, maintaining a stable level. The total liabilities were 144 million yuan, showing a similar slight downward trend, and the asset-liability ratio dropped from the initial 22.42% to 22.03%. This shows the company's good control of its liabilities.
More Unpleasant Surprises Could Be In Store For Jiangsu Sihuan Bioengineering Co., Ltd's (SZSE:000518) Shares After Tumbling 26%
No Data